CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 560 enrolled
Drug / intervention
Vonoprazan +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03219723
NCT03219723N/ACompleted
CompareCT.gov

Drug Use Surveillance of Takecab Tablets "Supplement to Helicobacter Pylori Eradication"

Takeda·observational·Posted Jul 17, 2017·Updated Mar 22, 2019

In Brief

An observational study evaluating Vonoprazan, Amoxicillin hydrate, and 2 other interventions for Gastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other. Completed, enrolled 560 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy on participants receiving first-line eradication and second-line eradication including vonoprazan (Takecab) tablets (triple therapy) in the routine clinical setting.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGastric/Duodenal Ulcer, Gastric MALT Lymphoma, Idiopathic Thrombocytopenic Purpura, or H. Pylori Gastritis, and Other
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 17, 2017
Enrollment StartSep 1, 2015
Primary CompletionApr 30, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.0 years ago

Interventions

Vonoprazandrug

Vonoprazan tablets

Amoxicillin hydratedrug

Amoxicillin hydrate (potency)

Clarithromycindrug

Clarithromycin (potency)

Metronidazoledrug

Metronidazole